2954-68-9

Usage

Uses

Used in Pharmaceutical Industry:
ETHYL 4-(4-METHOXY-3-METHYLPHENYL)-4-OXOBUTANOATE is used as a synthetic intermediate for the production of bioactive compounds, specifically antiproliferative calamenene-type sesquiterpenoids. These compounds, such as tavinin A (I) and epi-tavinin A (II), are derived from the Sterculia tavia plant and have demonstrated potential applications in the development of novel therapeutic agents.
Used in the Synthesis of Antiproliferative Compounds:
ETHYL 4-(4-METHOXY-3-METHYLPHENYL)-4-OXOBUTANOATE is used as a key building block in the synthesis of antiproliferative calamenene-type sesquiterpenoids, which are known for their potential to inhibit the proliferation of cancer cells. ETHYL 4-(4-METHOXY-3-METHYLPHENYL)-4-OXOBUTANOATE's unique structure allows for the creation of new molecules with enhanced biological activities, making it a valuable asset in the development of innovative cancer treatments.

InChI:InChI=1/C14H18O4/c1-4-18-14(16)8-6-12(15)11-5-7-13(17-3)10(2)9-11/h5,7,9H,4,6,8H2,1-3H3

Upstream product

• 14794-31-1 ethyl 3-(chloroformyl)propionate 
• 578-58-5 2-methylmethoxybenzene 
• 33446-14-9 4-(4-methoxy-3-methylphenyl)-4-oxobutyric acid 
• 64-17-5 ethanol 

Downstream Products

• 33446-14-9 4-(4-methoxy-3-methylphenyl)-4-oxobutyric acid 
• 362026-27-5 4-(4-methoxy-3-methylphenyl)-4-methyl-pentanoic acid ethyl ester 
• 98418-48-5 4-(4-methoxy-3-methylphenyl)-4-methyl-pentanoic acid 
• 77996-12-4 5-(4-methoxy-3-methyl-phenyl)-dihydro-furan-2-one 
• 77996-10-2 4-Hydroxy-4-(4-methoxy-3-methylphenyl)-5-methyl-hexanoic Acid Lactone 
• 77996-13-5 3,4-Dihydro-1-hydroxy-4-isopropyl-7-methoxy-1,6-dimethyl-2(1H)-naphthalenone 
• 77401-25-3 2,7-dihydroxycadalene 
• 70143-24-7 4-(4-methoxy-3-methylphenyl)-5-methylhexanoic acid 
• 68233-94-3 4‐isopropyl‐7‐methoxy‐1,6‐dimethylnaphthalen‐2‐ol 
• 87900-51-4 lacinilene C 
• 56051-00-4 1-hydroxy-4-isopropyl-7-methoxy-1,6-dimethylnaphthalen-2(1H)-one 
• 2102-75-2 7-hydroxycadalene 
• 1026083-33-9 4-[Hydroxy-(7-isopropoxy-6-methyl-1-oxo-1,2,3,4-tetrahydro-naphthalen-2-yl)-methyl]-benzoic acid methyl ester 
• 33446-15-0 4-(4-methoxy-3-methylphenyl)butyric acid 

Relevant academic research and scientific papers

Amines substituted with a dihydronaphthalenyl, chromenyl, or thiochromenyl group, an aryl or heteroaryl group and an alkyl group, having retinoid-like biological activity

Compounds of the formula where the symbols are as defined in the specification, have retinoid agonist, antagonist or negative hormone-like biological activity.

Amines substituted with a dihydronaphthalenyl, chromenyl, or thiochromenyl group, an aryl or heteroaryl group and an alkyl group, having retinoid-like biological activity

Compounds of the formula where the symbols are as defined in the specification, have retinoid agonist, antagonist or negative hormone-like biological activity.

A novel type of retinoic acid receptor antagonist: Synthesis and structure-activity relationships of heterocyclic ring-containing benzoic acid derivatives

A new series of heterocyclic ring-containing benzoic acids was prepared, and the binding affinity and antagonism of its members against all-trans- retinoic acid were evaluated by in vitro assay systems using human promyelocytic leukemia (HL-60) cells. Structure-activity relationships indicated that both an N-substituted pyrrole or pyrazole (1-position) and a hydrophobic region, with these linked by a ring system, were indispensable for effective antagonism. Among the compounds evaluated, optimal antagonism was exhibited by 4-[4,5,7,8,9,10-hexahydro-7,7,10,-10-tetramethyl-1-(3- pyridylmethyl)anthra[1,2-b]pyrrol-3-yl]benzoic acid (31), 4-[4,5,7,8,9,10- hexahydro-7,7,10,10-tetramethyl-1-(3-pyridylmethyl)-5-thiaanthra[1,2- b]pyrrol-3-yl]benzoic acid (40), and 4-[4,5,7,8,9,10-hexahydro-7,7,10,10- tetramethyl-1-(3-pyridylmethyl)anthra[2,1-d]pyrazol-3-yl]benzoic acid (55), all of which possess a 3-pyridylmethyl group at the five-membered ring nitrogen atom.